BioWorld

Jan. 31, 2003

FDA Response Letter Seen As Positive Sign For MedImmune

A complete response letter from the FDA regarding FluMist has elicited a positive reaction at MedImmune Inc., which also reported record revenue as part of its fourth-quarter and year-end earnings. (BioWorld Today) Read More

Affymetrix Signs $70M GeneChip Deal With Roche Diagnostics

As West Nile Encephalitis Virus Blankets North America, Authors Seek To Disarm Immune Attacks

Corixa, GSK Changing Terms Of Cancer Vaccine Agreement

Biotech Reps Square Off With Feds Over Reimbursement Rates

Elan Continues Divestiture With Product Sales To King

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 7, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...